Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Female Reproductive SystemDRG 755-malignancy-female-reproductive-system-with-cc
    Ask Trek AI about this page

    Malignancy, Female Reproductive System with CC: Inpatient Reimbursement Overview

    DRG 755 pertains to malignant neoplasms of the female reproductive system with a Complication or Comorbidity and defines the inpatient clinical population for payment grouping. It matters for inpatient reimbursement because the presence of a Complication or Comorbidity typically increases the relative resource intensity and influences Medicare Severity Diagnosis-Related Group–based payment.

    Customize your policy alerts

    Sign up for drg 755 policy alerts

    Get alerted when payer policies referencing 755 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 755 Overview

    DRG 755 covers hospital admissions for malignant neoplasms of the female reproductive system when a Complication or Comorbidity is present. This Diagnosis-Related Group groups patients with similar clinical characteristics and resource needs for inpatient care related to gynecologic malignancy plus an associated Complication or Comorbidity. It matters for Medicare payment because it helps determine prospective payment rates that reflect the increased resource use associated with comorbid conditions. Hospitals and coders use the DRG assignment to align clinical documentation and coding with Medicare Severity Diagnosis-Related Group payment policies.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute perioperative optimization and surgical outcomes studies: randomized or observational trials examine enhanced recovery protocols, blood management strategies, and perioperative chemotherapy timing in patients undergoing surgery for gynecologic malignancies (ovarian, uterine, cervical) with significant comorbidities. These studies focus on the inpatient acute-care period—preoperative risk stratification, intraoperative techniques to reduce blood loss and operative time, and immediate postoperative complications—to reduce length of stay and morbidity. Findings are directly relevant to hospital clinicians and payers because improved perioperative management can lower complication rates, shorten admissions, and reduce high-cost readmissions associated with this DRG.
    • Comparative effectiveness and sequencing studies of multimodality therapy in advanced or recurrent disease: prospective cohorts and pragmatic trials compare different combinations or sequencing of surgery, systemic therapy, and radiation for patients with high-risk or recurrent female reproductive malignancies who have concurrent conditions (the CC component). These trials enroll heterogeneous inpatient populations to evaluate real-world effectiveness, toxicities, and inpatient resource utilization of treatment pathways rather than isolated drug efficacy. Results inform clinicians and payers about which care pathways deliver better survival or quality-of-life benefits relative to hospital resource use and can guide coverage and care pathway design for patients assigned to this DRG.
    • Post-discharge outcomes, survivorship, and readmission-reduction studies: longitudinal observational studies and interventions test transitional care models, symptom-monitoring programs, and rehabilitation services for patients discharged after inpatient treatment for gynecologic cancers with complications or comorbidities. Research targets early post-discharge complications, management of treatment-related toxicities (eg, infections, thromboembolism), and coordination with outpatient oncology and primary care to prevent unplanned readmissions. This area matters to providers and payers because reducing readmissions and improving post-discharge functional recovery can lower total episode costs and improve quality metrics tied to reimbursement for patients in this DRG.

    Related Codes

    734-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITH-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy with CC/MCC: Inpatient Reimbursement Overview

    735-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITHOUT-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy: Inpatient Reimbursement Overview

    736-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    737-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    738-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    739-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    740-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    741-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    742-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITH-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy with CC/MCC: Inpatient Reimbursement Overview

    743-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy without CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 24

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.